UK Government’s Life Sciences Large Investment Portfolio: A New Era for British Life Science
The United Kingdom’s life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment Portfolio, a new flagship scheme designed to attract transformational investment into British pharmaceutical manufacturing and research and development. Announced alongside more than £80 million in fresh private investment unlocked through the existing Life Sciences Innovative Manufacturing Fund, the LSLIP represents one of the most ambitious structural commitments to the UK life sciences sector in recent years, and a central pillar of the government’s wider Life Sciences Sector Plan.
What Is the Life Sciences Large Investment Portfolio?
The Life Sciences Large Investment Portfolio is a government subsidy scheme operated through the Office for Life Sciences, designed to engage large companies that are prepared to commit investment portfolios exceeding £250 million into UK-based life sciences manufacturing and commercial research and development. The scheme carries an estimated budget of up to £570 million and is structured to run from October 2025 through to March 2030. Subsidies are awarded in the form of direct grants, covering a percentage of eligible project costs, with the maximum individual grant capped at £130 million.
To qualify, companies must be UK-registered, wholly private-sector businesses operating within the medicines, MedTech, or diagnostics sectors. Eligible expenditure includes capital costs related to manufacturing and research and development, encompassing fixed assets such as land, buildings, machinery, and equipment. Companies must be able to demonstrate a planned investment portfolio of at least £250 million over three years, with at least one eligible UK project commencing within 12 months. Individual projects within a portfolio must meet a minimum investment threshold of £8 million, consistent with the existing LSIMF framework.
A defining feature of the scheme is its offer of Trusted Trader status to qualifying companies, providing streamlined applications for financial support, tailored regional and national backing, and direct, sustained engagement with UK ministers. This positions LSLIP as more than a grant programme. It is designed to function as a high-level partnership framework between government and major global life sciences investors, removing friction from the investment process and providing the kind of institutional confidence that large-scale capital commitments require.
Building on Existing Foundations
The Life Sciences Large Investment Portfolio builds directly on the Life Sciences Innovative Manufacturing Fund, which has already proven its capacity to catalyse private investment at scale. An independent evaluation by Ipsos, published alongside the April 2026 announcements, confirmed that projects supported by the LSIMF and its predecessor fund between 2021 and 2023 helped unlock £12 of private investment for every £1 of grant funding. The LSIMF itself represents a £520 million commitment over five years and is on track to have channelled £1 billion of total investment into UK life sciences by the summer of 2026.
Science and Technology Secretary Liz Kendall, who announced the new scheme, framed it as evidence of the Life Sciences Sector Plan delivering results.
“By manufacturing more medicines in this country we can make sure more people get the vital treatments they need,” she said. “We are delivering the advanced treatments that patients need, growing our economy, and creating and protecting highly skilled jobs for people across the UK.”
The April 2026 Investment Announcements
The formal launch of the LSLIP was accompanied by announcements of more than £80 million in new investment from three companies, bringing the total amount invested in UK life sciences in 2026 to £600 million.
The largest single commitment came from Accord Healthcare, one of the largest suppliers of oncology and chemotherapy medicines in Europe, which announced an investment of more than £45 million in its Barnstaple site in North Devon. The funding will support the manufacture of two new innovative medicines, including treatments for people living with bipolar disorder, alongside the site’s established expertise in generic medicines. Accord’s Barnstaple facility supplies medicines that account for 9% of all NHS prescriptions and is one of the most important employers in the region. Paul Tredwell, Chief Executive Officer of Accord, said the LSIMF grant had helped unlock new investment in the site, adding that the investment “will enable the manufacture of 2 new innovative medicines, helping to secure the sustainability of the site and its broader contribution to UK health resilience.”
The University of Birmingham’s Precision Health Technologies Accelerator announced a £10 million investment to establish a new near-patient biomanufacturing facility, including three clean rooms dedicated to producing medicines and vaccines for patients and clinical trials. The facility will support advanced cell and gene therapies and mRNA vaccine development, and will complement work already under way at the University, including Europe’s first trial of a personalised mRNA vaccine for pancreatic cancer, conducted alongside University Hospitals Birmingham NHS Foundation Trust.
Professor Gino Martini, Chief Executive Officer of the PHTA, highlighted the strategic importance of the facility.
“The UK, and particularly the West Midlands, urgently needs GMP cleanroom facilities to support the production of Advanced Therapy Medicinal Products and vaccines, including cell therapies and mRNA vaccines, as well as medicines for clinical trials,” he said.
The third investment came from Codis, which committed to developing a new facility in Haverhill, Suffolk, using advanced spray-drying technology to support next-generation therapies for conditions including cancer and neurodegenerative diseases. The investment will create 29 new jobs and safeguard a further 160 roles, and will see Haverhill install the UK’s only commercial-scale, solvent-capable GEA PSD 4 spray dryer, a technology that improves the bioavailability of difficult-to-manufacture medicines.
Regional Pilots: Liverpool and Manchester
A distinctive and forward-looking element of the LSLIP is its regional dimension. The scheme’s regional support package has been initially piloted in Liverpool and Manchester, two of the UK’s most significant life sciences clusters, with the aim of demonstrating how greater collaboration between local institutions and national government can attract transformational investment to areas beyond London and the South East.
Steve Rotheram, Mayor of the Liverpool City Region, described the pilot as a powerful endorsement of the region’s capabilities. Liverpool is home to the world’s first dedicated school of tropical medicine and a new Life Sciences Innovation Zone set to unlock up to £800 million in public and private investment and create 8,000 high-quality jobs. “Being chosen to pilot the new Life Sciences Large Investment Portfolio gives us the platform to go further and faster, attracting major global investment, accelerating cutting-edge research, and ensuring that scientific breakthroughs translate into well-paid, high skilled jobs and real improvements in people’s lives,” Rotheram said.
Andy Burnham, Mayor of Greater Manchester, pointed to the region’s position as the UK’s fastest-growing economy and its record of attracting foreign direct investment. “Life sciences has been one of the key sectors behind that growth, and in the past year alone we’ve seen companies like IQVIA, Convatec and Vortex Biotech establishing themselves here,” he said. Greater Manchester’s offer to investors centres on the Oxford Road Corridor, a dense concentration of research institutions, NHS assets, and innovation infrastructure that has made it one of Europe’s leading life science ecosystems.
A Broader Strategic Picture
The LSLIP arrives at a moment of considerable momentum for UK life sciences policy. The April 2026 announcements follow the recent finalisation of a trade arrangement that makes the UK the first country in the world to secure 0% tariffs on pharmaceutical exports to the United States, a development that significantly improves the economics of UK-based manufacturing for globally operating companies. This forms a key pillar of the Life Sciences Sector Plan within the government’s broader Modern Industrial Strategy.
The scheme also arrives in a context shaped by heightened awareness of pharmaceutical supply chain vulnerability, following disruptions caused by the closure of the Strait of Hormuz in early 2026. The case for domestic manufacturing resilience has rarely been more visible, and the LSLIP’s explicit focus on expanding UK manufacturing capability positions it as both an economic growth programme and a strategic response to the fragility of internationally dispersed supply chains.
For global life sciences companies evaluating their manufacturing and research footprint, the Life Sciences Large Investment Portfolio represents a structured, government-backed route into one of the world’s most scientifically productive life science markets, with a package of financial, institutional, and regional support designed to reduce the barriers to large-scale, long-term commitment.
